|Mr. Gary S. Titus CPA||Chairman and Corp. Sec.||72.25k||N/A||57|
|Dr. Anthony J. Gringeri Ph.D.||Chief Exec. Officer, Pres and Director||368.99k||N/A||64|
|Dr. John S. Yu M.D., Ph.D.||Founder & Director||N/A||N/A||53|
|Mr. David E. Fractor CPA||Chief Financial Officer||202.5k||N/A||57|
|Dr. Steven J. Swanson M.D., Ph.D.||Sr. VP of Research||313.57k||N/A||61|
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.
ImmunoCellular Therapeutics, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.